Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial

European heart journal. Cardiovascular pharmacotherapy

Volumn 3, Issue 2, 2017, Pages 92-97

  Hartman, Otto ^a   Kovanen, Petri T ^b   Lehtonen, Jukka ^a   Eklund, Kari K ^c   Sinisalo, Juha ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b WIHURI RESEARCH INSTITUTE   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Acute coronary syndrome; Anti inflammatory; Atherosclerosis; Coronary artery disease; Hydroxychloroquine; inflammation; Myocardial infarction

Indexed keywords

ANTIRHEUMATIC AGENT; HYDROXYCHLOROQUINE;

ATHEROSCLEROSIS; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HEART INFARCTION; HUMAN; MULTICENTER STUDY; PILOT STUDY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SECONDARY PREVENTION;

ANTIRHEUMATIC AGENTS; ATHEROSCLEROSIS; DOUBLE-BLIND METHOD; HUMANS; HYDROXYCHLOROQUINE; MYOCARDIAL INFARCTION; PILOT PROJECTS; RECURRENCE; SECONDARY PREVENTION;

EID: 85041467933     PISSN: None     EISSN: 20556845     Source Type: Journal    
DOI: 10.1093/ehjcvp/pvw035     Document Type: Article

References (0)